BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 25, 2025
Home » Authors » Meg Bryant

Meg Bryant

Articles

ARTICLES

Medtronic Neurovascular Co-Lab platform aims to spur advances in stroke treatment

Oct. 26, 2022
By Meg Bryant
Medtronic plc has launched Medtronic Neurovascular Co-Lab platform, a major initiative to speed the pace of innovations in stroke treatment and access for patients around the world. The neurovascular innovation incubator will bring together innovators, entrepreneurs and physicians to collaborate and share their ideas about promising products and solutions.
Read More
Artificial intelligence and digital health icons

Clario develops blueprint for AI use in decentralized clinical trials

Oct. 21, 2022
By Meg Bryant
Endpoint solutions company Clario Inc. has published a roadmap on how artificial intelligence (AI) can be used to improve the experience of patients participating in decentralized clinical trials (DCTs).
Read More
Axoft

Axoft launches with $8M for brain-machine interface implants

Oct. 19, 2022
By Meg Bryant
Axoft Inc. emerged from stealth mode with an $8 million seed round led by The Engine, the Massachusetts Institute of Technology’s venture spinout for early-stage tech startups. The funds will be used to conduct preclinical studies and scale up prototypes of its supple brain implant technology.
Read More
Synaptive-Panaxium

Synaptive Medical, Panaxium team up to improve brain mapping

Oct. 14, 2022
By Meg Bryant
Synaptive Medical Inc. and Panaxium SAS have inked a deal to bring high-resolution, real-time, artificial intelligence (AI)-assisted cortical mapping to neurosurgeons. Under the collaboration, Synaptive’s Modus V robotic exoscope technology will be integrated with Panaxium’s ultra-flexible iontronic electrocorticography (ECoG) platform.
Read More
Rsip Vision featured

Rsip Vision releases tool for 3D ureter reconstruction

Oct. 11, 2022
By Meg Bryant
Rsip Vision Ltd. has debuted a new tool for making 3D reconstructions of the ureter. The vendor-neutral tool, which uses artificial intelligence (AI) and deep-learning algorithms to make 3D reconstructions, is available to third-party medical device companies using three-arm imaging and viewer solutions.
Read More
Flower with dollar sign

Cranius raises $19.4M for device to treat chronic brain disease

Oct. 3, 2022
By Meg Bryant
Recent years have seen progress in treating brain disease, but one major challenge remains: getting therapeutic treatments across the blood-brain barrier. Now, Cranius LLC has raised $19.4 million to advance a device designed to bypass the blood-brain barrier and deliver medicines directly and continuously to the brain.
Read More
Stryker - Q Guidance System

Stryker launches Q Guidance system for spine surgeries

Sep. 30, 2022
By Meg Bryant
Stryker Corp. reported the launch of its Q Guidance system for spine applications. The system leverages new optical tracking options via a redesigned camera with the advanced algorithms of the newly released Spine Guidance software.
Read More
Surge

Surge reels in $2.6M for AI-driven predictive surgery platform

Sep. 27, 2022
By Meg Bryant
Life science startup Surge Inc. raised $2.6 million in a financing led by Hcvd and Boutique Venture Partners. The funds will be used to advance its artificial intelligence (AI)-powered technology aimed at making a patient’s surgical journey safer.
Read More
A laboratory technician waits for a vial to fill with blood from a patient.

Ampel’s genomic blood test detects and predicts severity of COVID-19

Sep. 23, 2022
By Meg Bryant
As doctors and public health officials brace for a possible fall coronavirus surge, one of the challenges continues to be predicting who will have a mild, moderate or severe case of COVID-19.
Read More
SENTINEL
TCT 2022

Boston Sci’s PROTECTED TAVR trial misses primary endpoint, but some see benefit

Sep. 19, 2022
By Meg Bryant
Boston Scientific Corp.’s Sentinel cerebral protection system missed its primary endpoint of reduced stroke in the PROTECTED TAVR clinical trial. The data did, however, show a significant reduction in risk of disabling stroke in the immediate days after a transcatheter aortic valve replacement (TAVR) procedure.
Read More
View All Articles by Meg Bryant

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing